Blinatumomab — nowy lek u chorych na nawrotową/ /oporną ostrą białaczkę limfoblastyczną
Haematologia(2017)
摘要
The long term prognosis of adult patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) is poor. There is no standard treatment for relapsed ALL and reinduction therapy should only be a “bridge treatment” in allogeneic hematopoietic stem cell transplantation (allo- -HSCT). In spite of obtaining an initial response to treatment, the duration of response using standard chemotherapy is usually short and the next relapses are chemoresistant. Immunotherapy with monoclonal antibodies as a targeted therapy represents a novel approach for treating patients with R/R ALL. The objective of immunotherapy is to improve the relapse-free and overall survival without increasing the toxicity of treatment. In this review, the mechanism of action and clinical efficacy of the novel bispecific antibody blinatumomab is discussed. The European Medicines Agency approved blinatumomab in 2015 for treating adult patients with Philadelphia chromosome negative R/R B-ALL.
更多查看译文
关键词
Treatment Outcomes
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要